Pulling SEC filings + quote and writing the call…

HAWKINS INC
Next earnings Jul 28, 2026 · consensus $1.44 EPS, $320M rev
Last earnings -4.0% on 2026-05-13
Quality specialty-chemicals transformation, but FY26 EPS slipped while the multiple stayed rich — own it, don't add up here.
Revenue $1.08B · FY2026
Middling fundamentals and a rich price (~59% above fair value) leave little margin of safety — a wait-and-see.
Hawkins is a real business in transition: management is deliberately repositioning from a 'bulk commodity distributor into a specialty ingredients company,' realigning into three new segments and spending aggressively to get there. FY26 revenue jumped 11.2% to $1.08B and operating cash flow surged 29.9% to $144M, but GAAP diluted EPS actually fell 3.0% to $3.91 — the first earnings decline after three years of clean expansion ($51.5M → $60.0M → $75.4M → $84.3M → $81.5M). Management points to pro-forma diluted EPS of $3.95 (+9%) to bridge the gap, which tells you acquisition/integration drag is the culprit, not core demand.
The balance sheet has shifted noticeably. Six FY26 acquisitions — anchored by WaterSurplus at $149.9M plus an earnout of up to $53.7M — pushed long-term debt up 63.8% to $244M and total liabilities up 46.0%, against cash of just $3.91M. Equity still grew 16.0% to $534M and L/E at 0.85x is manageable, but the cushion is thin and capex was $58.2M (+41.7%), so free-cash conversion will be the variable to watch as integrations close. ROE held at 15.3%, gross margin at 22.6% and operating margin at 11.2% — respectable for a distributor, unremarkable for a 'specialty' multiple.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 25, 2026, 9:33 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Is HWKN a buy? The one-page verdict, explained →
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | $775M | $935M | $919M | $974M | $1.08B |
| Gross profit | $147M | $165M | $194M | $226M | $245M |
| Operating income | $71.2M | $88.2M | $104M | $119M | $121M |
| Net income | $51.5M | $60.0M | $75.4M | $84.3M | $81.5M |
| Diluted EPS | $2.44 | $2.86 | $3.59 | $4.03 | $3.91 |
| Net margin | 6.7% | 6.4% | 8.2% | 8.7% | 7.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual proxy: routine director elections, auditor ratification, say-on-pay
Officer/director change (Item 5.02); no financial impact disclosed
FY26: sales +11%, OCF +30%, but EPS -3% on $150M WaterSurplus deal dilution
FY26: sales +11%, OCF +30%, but EPS -3% on $150M WaterSurplus deal dilution
Q3 FY26 results reflecting acquisition-driven growth and segment realignment
Q3 FY26 results reflecting acquisition-driven growth and segment realignment
Executive officer change announcement (Item 5.02)
Q2 FY26: WaterSurplus integration in full swing; debt rising to fund M&A
Q2 FY26: WaterSurplus integration in full swing; debt rising to fund M&A
Sources: SEC EDGAR (CIK 0000046250, latest 10-K filed 2026-05-13) · EODHD · Proprietary analysis · as of 6/25/2026, 1:33:26 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2026-05-13 | Rozeboom Shirley A. VP HEALTH AND NUTRITION | Award | 1.91K | |
| 2026-05-13 | Lange Douglas A. VP - WATER TREATMENT GROUP | Award | 1.99K | |
| 2026-05-13 | Oldenkamp Jeffrey P. EXECUTIVE VP AND CFO | Award | 8.44K | |
| 2026-05-13 | Grahek Drew M. VICE PRESIDENT OF OPERATIONS | Award | 2.70K | |
| 2026-05-13 | Mangine David J. VP-INDUSTRIAL SOLUTIONS GROUP | Award | 1.91K | |
| 2026-05-13 | Jones Gregory Alan VP of Food and Health Sciences | Award | 1.97K | |
| 2026-05-13 | Hawkins Patrick H. CEO AND PRESIDENT | Award | 16.9K | |
| 2026-03-30 | Rozeboom Shirley A. VP HEALTH AND NUTRITION | Tax | 3.61K @ $151.62 | $547K |
| 2026-03-30 | Lange Douglas A. VP - WATER TREATMENT GROUP | Tax | 3.85K @ $151.62 | $584K |
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1195 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.